Compass announces first patient dosed in Phase 1b CTX-471 combination trial

Compass Therapeutics (CMPX) announced that the first patient has been dosed in the Phase 1b study of CTX-471 in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with advanced solid tumors. CTX-471 is supplied by Compass, which is also the sponsor of this study, and KEYTRUDA will be supplied by Merck (MRK) under a clinical collaboration and supply agreement between the companies. This study enrolls patients with metastatic or locally advanced non-small cell lung cancer, melanoma, small cell lung cancer, mesothelioma, and head and neck cancer that have progressed after treatment with a checkpoint inhibitor. CTX-471 has completed a Phase 1 dose escalation and cohort expansion study, where it was shown to be well-tolerated. The Phase 1b monotherapy study is fully enrolled and ongoing. In this study, CTX-471 has been evaluated as a monotherapy treatment in patients with advanced solid tumors who received at least one checkpoint inhibitor post progression.